Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Etoposide
Radiation: Thoracic Radiation Therapy (TRT)
Drug: Vinorelbine
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-05-30

Last Posted Date: 2016-06-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 598

Registration Number: NCT00686959

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer

Phase 3

Conditions: Esophageal Cancer

Interventions: Drug: Paclitaxel
Drug: Cisplatin
Drug: Tarceva
Radiation: Radiotherapy

First Posted Date: 2008-05-29

Last Posted Date: 2014-04-29

Lead Sponsor: Wenzhou Medical University

Target Recruit Count: 344

Registration Number: NCT00686114

Locations: 🇨🇳
1st affliated hospital of Wen Zhou Medical college, Wen Zhou, Zhejiang, China

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Phase 2

Completed

Conditions: Transitional Cell Carcinoma

Interventions: Drug: Paclitaxel

First Posted Date: 2008-05-23

Last Posted Date: 2016-10-17

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 48

Registration Number: NCT00683059

Locations: 🇨🇦
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 2 locations

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: cisplatin
Drug: everolimus
Drug: paclitaxel

First Posted Date: 2008-05-20

Last Posted Date: 2013-03-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 18

Registration Number: NCT00680758

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Sarah Cannon Cancer Center at Centennial Medical Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Phase 2

Terminated

Conditions: HER2-negative Breast Cancer
Stage IIIC Breast Cancer
Stage II Breast Cancer
Stage IIIB Breast Cancer
Stage IIIA Breast Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: bevacizumab
Drug: paclitaxel
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis
Biological: pegfilgrastim

First Posted Date: 2008-05-16

Last Posted Date: 2023-12-11

Lead Sponsor: University of Nebraska

Target Recruit Count: 15

Registration Number: NCT00679029

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Phase 1

Completed

Conditions: Breast Cancer
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Melanoma (Skin)
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2008-04-28

Last Posted Date: 2011-05-10

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 16

Registration Number: NCT00667641

Locations: 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: docetaxel
Drug: lapatinib ditosylate
Drug: paclitaxel

First Posted Date: 2008-04-28

Last Posted Date: 2022-08-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 652

Registration Number: NCT00667251

Locations: 🇬🇧
Novartis Investigative Site, York, United Kingdom

Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers

Phase 1

Completed

Conditions: Peritoneal Neoplasms

Interventions: Drug: nanoparticulate paclitaxel

First Posted Date: 2008-04-25

Last Posted Date: 2014-02-27

Lead Sponsor: CritiTech, Inc.

Target Recruit Count: 22

Registration Number: NCT00666991

Locations: 🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸
Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: ASA404
Drug: carboplatin
Drug: Paclitaxel

First Posted Date: 2008-04-21

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1285

Registration Number: NCT00662597

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Sinai Hospital of Baltimore - The Alvin & Lois Lapidus Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Arlington Cancer Center, Arlington, Texas, United States

and more 98 locations

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

Phase 1

Terminated

Conditions: Stage IIIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer

Interventions: Drug: vorinostat
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2008-04-21

Last Posted Date: 2017-06-14

Lead Sponsor: University of Washington

Target Recruit Count: 5

Registration Number: NCT00662311

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy